Cysteine variants of granulocyte-macrophage colony-stimulating factor

Patent Number: 7,148,333

G-CSF is a potent hematopoietic stem cell growth factor used clinically under the name Neupogen, made by Amgen, for accelerating granulopoiesis. One of the disadvantages of protein therapeutics in general is poor bioavailability and short half life.

The current patent discloses methods of modifying G-CSF so as to allow for site-specific
conjugation with polyethylene glycol which is generally non-antigenic, inert, and allows for enhanced half-life. Various compositions of matter of the G-CSF variants are disclosed.

According to the Assignee's website, the company is still in preclinical phases of development with various protein therapeutic products. The contacts for the company are below:

Bolder BioTechnology, Inc.
2945 Wilderness Place, Suite 100
Boulder, CO 80301
Telephone 303-420-4420
Fax 303-420-4426
Licensing Contact:
George (Joe) Cox, Ph.D., President
jcox@bolderbio.com

View this patent on the USPTO website.